Clinical trials: PET Positive
Hodgkin Lymphoma
Early Chemotherapy Intensification in Interim-Positron Emission Tomography (PET) Positive Hodgkin Lymphoma
Early interim-PET after two courses of chemotherapy is a powerful outcome predictor in advanced-stage Hodgkin Lymphoma (HL) patients treated with adriamycin (doxorubicin), bleomycin, vinblastine and dacarbazine (ABVD).
- Trial name
- NCT00877747
- Where
- Italy
- Volunteers
- 160 people
- Sponsor
- Ospedale Santa Croce-Carle Cuneo
Breast Carcinoma
ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients
Eclectic is a strategy trial; once the class of treatment (endocrine therapy or chemotherapy) has been allocated according to 16α-18F-fluoro-17β-oestradiol (18F-FES) Positron Emission Tomography/Computed Tomography (PET/CT)…
- Trial name
- ECLECTIC (NCT06195709)
- Testing
- Endocrine therapy, Endocrine therapy combined with the local treatment of FES-negative lesions, Chemotherapy
- Where
- 21 sites in France
- Volunteers
- 300 people
- Sponsor
- Institut Curie
FAP- Expressing Positive Tumors, RGD- Expressing Positive Tumors
Diagnosis of Metastatic Tumors on 68Ga-FAPI-RGD PET-CT and Radioligand Therapy With 177Lu-FAPI-RGD
FAP and RGD are overexpressed in many tumor tissues. This study is intended to conduct preliminary clinical transformation and internal irradiation dosimetry research on 177Lu-FAPI-RGD--a new dual-targeted 177Lu therapeutic drug…
- Trial name
- NCT06638034
- Testing
- 68Ga-FAPI-RGD for PET / CT scan and 177Lu-FAPI-RGD for therapy
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Peking Union Medical College Hospital
Lung Cancer
Methylprednisolone Before Fludeoxyglucose-Labeled Positron Emission Tomography in Patients With Lung Cancer
The purpose of this study is to determine whether giving an anti-inflammatory medication (corticosteroid) prior to a positron emission tomography scan (PET) scan may reduce or eliminate false findings related to inflammation
- Trial name
- NCT01789892
- Testing
- methylprednisolone, fludeoxyglucose F 18, positron emission tomography
- Sponsor
- Ohio State University Comprehensive Cancer Center
HPV Positive Oropharyngeal Squamous Cell Carcinoma
De-escalation of Radiation Dose in HPV-associated OPC Utilising FMISO PET (DE-RADIATE)
The goal of this prospective clinical trial is to determine if HPV-associated oropharyngeal squamous cell carcinoma that is non-hypoxic on FMISO PET can be successfully treated with a lower dose of radiation therapy.
- Trial name
- DE-RADIATE (NCT06307015)
- Testing
- De-escalation, Standard of care
- Where
- Australia
- Volunteers
- 25 people
- Sponsor
- Royal North Shore Hospital
Breast Cancer
18F-fluoroestradiol (18F-FES) PET/CT Guided First-line Treatment for HR+/HER2- Metastatic Breast Cancer Patients
A single-center, real world study to evaluate the role of FES-PET in guiding the first-line treatment of HR+/HER2- MBC patients.
- Trial name
- NCT06655545
- Where
- China
- Volunteers
- 473 people
- Sponsor
- Fudan University
Breast Cancer
FES-PET for Patients Treated on NCI Protocol 8762
A significant number of all invasive breast cancers are hormone sensitive and may be candidates for treatment with hormonal therapy.
- Trial name
- NCT01714128
- Testing
- Diagnostic Imaging ( 6α-[18F]fluoro-17β-estradiol (FES))
- Where
- United States
- Sponsor
- Washington University School of Medicine
Cervical Cancer, Stage IB Cervical Cancer
Proton Beam Radiation Therapy and Cisplatin in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer and Positive Lymph Nodes
RATIONALE: Specialized radiation therapy, such as proton beam radiotherapy, that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Conditions
- Cervical Cancer, Stage IB Cervical Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer
- Trial name
- NCT01019278
- Testing
- proton beam radiation therapy, radiation therapy treatment planning/simulation, cisplatin
- Sponsor
- Abramson Cancer Center at Penn Medicine
Urinary Bladder Neoplasms, Colorectal Cancer
A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours
A Phase I/IIa First-in-human, Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8853 in Participants with Selected Advanced/Metastatic Solid Tumours.
- Conditions
- Urinary Bladder Neoplasms, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT05397171
- Testing
- AZD8853, Zirconium-89 crefmirlimab berdoxam
- Where
- 6 sites in United States, Canada
- Volunteers
- 17 people
- Sponsor
- AstraZeneca
Metastatic Prostate Adenocarcinoma, PSMA PET-Positive Castration-Resistant Prostate Cancer
Kuopio Lutetium-177 Study in Patients with PSMA-Positive Metastatic Prostate Cancer
KuPSMALu-trial is an observational study for patients treated with 177LuPSMA-I\&T in Kuopio University Hospital, Finland. Study focuses on efficacy, safety and biomarker research.
- Trial name
- KuPSMALu (NCT06850545)
- Where
- Finland
- Volunteers
- 150 people
- Sponsor
- Kuopio University Hospital
Advanced Breast Cancer
Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)
CDK4/6 inhibitors are currently the standard treatment for female breast cancer patients with HR+ tumors. However, there is no established standard treatment for patients who experience treatment failure with CDK4/6 inhibitors.
- Trial name
- NCT05861830
- Testing
- The combination of Dalpiciclib with physician-selected endocrine therapy, Chemotherapy selected by the physician
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking Union Medical College Hospital
Breast Cancer
Comparison Between ER Loss and Triple-Negative Breast Cancer Guided by 18F-FES PET/CT in Metastatic Breast Cancer
This study aimed to compare survival outcomes and clinical characteristics between ER loss and metastatic triple-negative breast cancer (mTNBC) patients, exploring the prognostic implications of dynamic ER changes.
- Trial name
- NCT07316439
- Where
- China
- Volunteers
- 197 people
- Sponsor
- Fudan University
Breast Cancer
Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.
The study assess the early metabolic effects of neoadjuvant treatment with trastuzumab and pertuzumab (± endocrine therapy) on the primary tumor and axillary lymph nodes and their predictive value for pathologic complete response…
- Trial name
- PHERGain (NCT03161353)
- Testing
- Perjeta, Herceptin, Docetaxel
- Where
- 56 sites in Belgium, France and 5 more
- Volunteers
- 377 people
- Sponsor
- MedSIR
PSMA Positive Tumors or Tumor Tissues, Cancer
Diagnostic Performance of PET/CT-PSMA in Patients With Non-prostatic PSMA-expressing Neoplasms
Study to collect data from PET/CT-PSMA performed in patients with neoplasms expressing PSMA, other than prostate cancer. Objectives The primary objective is to evaluate the diagnostic performance of PET/CT-PSMA in the staging and…
- Trial name
- MORE-PSMA (NCT06835244)
- Testing
- 68Ga-PSMA-11
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Carcinoid Tumors, Islet Cell (Pancreatic NET)
68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
The primary objective of the study is to evaluate 68Ga-DOTA TATE PET/CT for staging and monitoring response to chemotherapy in patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing…
- Conditions
- Carcinoid Tumors, Islet Cell (Pancreatic NET), Other Neuroendocrine Tumors
- Trial name
- NCT01980732
- Testing
- 68Ga-DOTA TATE
- Where
- United States
- Sponsor
- Andrei Iagaru
Estrogen Receptor Positive, HER2/Neu Negative
FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
This clinical trial studies fluorine F 18 fluorothymidine (FLT) positron emission tomography (PET) in measuring treatment response in patients with newly diagnosed estrogen receptor (ER)-positive, human epidermal growth factor…
- Conditions
- Estrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma, Stage IA Breast Cancer
- Trial name
- NCT01928186
- Testing
- Fluorothymidine F-18, Positron Emission Tomography, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Washington
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma
Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer
This phase II trial tests how well stereotactic body radiation therapy (SBRT) works in treating patients with estrogen receptor positive (ER +) breast cancer that has spread from where it first started to other places in the body…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, Metastatic Breast Carcinoma
- Trial name
- NCT06260033
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
Tuberculosis, Pulmonary
Fibroblast Activating Protein (FAP) PET/CT in Adults With Tuberculosis
This is an early phase study in patients with Tuberculosis (TB) to evaluate Fibroblast Activating Protein (FAP) activation as a marker of fibrosis.
- Trial name
- NCT07830771
- Testing
- [18F]-FAPI-74
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Pennsylvania
Breast Cancer Invasive, Node Positive Breast Cancer
Exploring the Tumor Micro-Environment with 68Ga-FAPi-46 PET/CT in Breast Cancer
This study is a prospective, non-interventional, open-label study to evaluate the glucose metabolism and the expression of the imaging agent 68 Gallium-Fibroblast Activation Protein Inhibitor-46 (68Ga-FAPi-46) with PET imaging…
- Trial name
- FAPI-PET (NCT06790264)
- Testing
- 68Ga-FAPi-46 PET/CT
- Where
- Italy
- Volunteers
- 92 people
- Sponsor
- European Institute of Oncology
Latent Tuberculosis
Determining Risk in Latent Tuberculosis
Background: Tuberculosis (TB) is a leading cause of death worldwide. Those who are exposed to the TB bacteria but have not become sick are said to have latent TB.
- Trial name
- NCT01571739
- Where
- South Korea
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)